Site-Specific Integration technology, which is a novel approach based on gene editing technology for the development and production of biopharmaceuticals. It can precisely locate and treat diseases in specific cells, thereby reducing the side effects of treatment, and has attracted the attention of many well-known pharmaceutical companies internationally.

According to public information: CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Arvinas, Precision BioSciences, Sutro Biopharma, Horizon Discovery Group, Cellectis, Alligator Bioscience and other international pharmaceutical companies are using Site-Specific Integration technology to develop gene editing drugs to treat hereditary diseases. Disease, cancer and other health problems. Site-specific integration technology has become a hot topic in the field of biopharmaceuticals, and is considered to be an important development direction in the field of biopharmaceuticals.

These companies are seeking to use site-specific integration technologies to develop drugs to treat a range of diseases, including cancer, genetic, immune and neurological disorders. We can take a look at the progress three of these companies have made using point integration technology.

CRISPR Therapeutics, a biopharmaceutical company using Site-Specific Integration technology, has been working on the development of biopharmaceuticals using gene editing technology. CRISPR Therapeutics has teamed up with Vertex Pharmaceuticals to develop a drug based on CRISPR-Cas9 gene editing technology to treat genetic diseases. In addition, the company collaborated with Berlin-Chemie AG/Menarini Group to develop a biologic drug for the treatment of blood diseases. And, CRISPR Therapeutics is collaborating with other companies and institutions to develop biological drugs for the treatment of cancer, genetic diseases and immune diseases.

Editas Medicine has partnered with Allergan to develop an ophthalmic drug using CRISPR-Cas9 gene editing technology to treat an inherited eye disease. The company has partnered with Vertex Pharmaceuticals to develop a biologic drug for the treatment of genetic diseases. In addition, Editas Medicine is conducting a series of clinical trials to evaluate the effectiveness of its biopharmaceuticals using gene editing technology in the treatment of cancer, genetic diseases and eye diseases.

Intellia Therapeutics is running a series of clinical trials evaluating its biopharmaceuticals using CRISPR-Cas9 gene-editing technology to treat genetic diseases and cancer. The company has partnered with Novartis to develop a biologic drug for the treatment of blood cancers, and Intellia Therapeutics has received FDA clearance to conduct clinical trials in the United States.

It is clear that the potential of site-integrated technologies in biopharmaceuticals has already begun to emerge. The field of biopharmaceuticals is developing rapidly, and site-specific integration technology, as an emerging field, provides hope for the development of more biopharmaceuticals based on gene editing technology in the future.

Note: Some of the content of this article is derived from public information on the Internet.